Table 1 Patient characteristics, treatment and toxicity
No | % | |
|---|---|---|
Total number | 36 | |
Sex M/F | 21/15 | 58/42 |
Median age (range), years | 55 (33–63) | |
Histology | ||
Grade 1 | 16 | 44 |
Grade 2 | 12 | 33 |
Grade 3 | 8 | 22 |
Ann Arbor stage | ||
I | 2 | 6 |
II | 1 | 3 |
III | 6 | 16 |
IV | 27 | 75 |
FLIPI | ||
Low | 13 | 36 |
Intermediate | 16 | 44 |
High | 7 | 19 |
BM involvement | 27 | 75 |
No. of previous treatments | ||
1 | 35 | 97 |
2 | 1 | 3 |
Months from last therapy, median (range) | 21 (2–113) | |
Treatment after high-dose (HD)-araC | ||
Group 1: BEAM/M-M | 7 | 19 |
Group 2: Melphalan, BEAM/M-M | 6 | 16 |
Group 3: HD-VP16, BEAM/M-M | 7 | 19 |
Group 4: dexaBEAM, BEAM/M-M | 16 | 44 |
No. of death | 10 | 28 |
Causes of death | ||
Infections | 5 | 14 |
Myelodysplasia | 1 | 3 |
Other tumor | 1 | 3 |
Progressive disease | 3 | 8 |
